Navigation Links
BioBDx to Present at the 2012 BioPharm America and AdvaMed MedTech Conferences in Boston
Date:9/17/2012

PLYMOUTH MEETING, Pa., Sept. 17, 2012 /PRNewswire/ -- BioBehavioral Diagnostics (BioBDx) announced today that Calvin Sumner M.D., chief medical officer and SVP of clinical development, will be presenting at the BioPharm America Conference taking place September 19-21, 2012 and Byron Hewett, chairman and CEO, will be presenting at the AdvaMed MedTech Conference taking place October 1-3, 2012, both in Boston, MA.

BioBDx manufactures and markets the Quotient® System, a tool that objectively measures brain functions related to deficits in response inhibition. The first FDA-cleared application of this platform technology is the objective measurement of hyperactivity, impulsivity and inattention as an aid in the assessment of attention-deficit hyperactivity disorder (ADHD). 

Dr. Sumner and Mr. Hewett will provide a company overview and update on the Quotient System during their presentations:

 Event:BioPharm America 2012 ConferenceDate: Friday, September 21, 2012 Time: 10:25 am ETLocation:Hancock Room; Westin Boston WaterfrontEvent:AdvaMed 2012 MedTech ConferenceDate: Tuesday, October 2, 2012 Time: 11:10 am ETLocation:Room 051; Boston Convention & Exhibition Center 

About the Quotient® ADHD TestThe Quotient® ADHD Test measures motion and analyzes shifts in attention state to give an objective picture of the core symptom areas of ADHD.  Clinicians use the Quotient® ADHD Test at the initial visit to assess severity of the three core symptoms of ADHD; hyperactivity, inattention and impulsivity.  Patients may be re-assessed periodically at follow-up visits to guide treatment plans.  The clinician integrates the Quotient® report with information from other assessment tools and the clinical evaluation to help guide the discussion on the treatment plan. For more information please visit: http://www.biobdx.com/products

About BioBehavioral Diagnostics CompanyBioBDx manufactures and markets the Quotient System, a tool that aids in the objective and accurate assessment of neural control functions related to deficits in inhibitory control.  We are dedicated to providing physicians, parents and patients high-value information to guide personalized strategies and enhance quality of life for patients with ADHD.  Our vision is to provide accurate tools for the diagnosis and management of neurological and psychiatric conditions, leading to a transformation of behavioral medicine.  Founded in 2006, BioBDx is a privately held company.

Contacts:BioBDxByron Hewett

Chairman and Chief Executive Officer

484-532-2201

Byron_Hewett@BioBDx.comMedia/Investors:Tiberend Strategic Advisors, Inc.

Claire Sojda

212-827-0020

csojda@tiberend.com 


'/>"/>
SOURCE BioBehavioral Diagnostics Company
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
2. BioSpecifics Technologies Corp. To Present at UBS Global Life Sciences Conference
3. BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
4. Representatives Betty McCollum (MN) and Steven LaTourette (OH) to Receive USGS Coalition Leadership Award
5. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
6. Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of Solithromycin at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
7. Lexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
8. Isis Pharmaceuticals To Present At Two Upcoming Investor Conferences
9. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
10. Onyx Pharmaceuticals To Present At Upcoming Investor Conferences
11. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
Breaking Biology News(10 mins):